The two-year shortage of Eli Lilly’s blockbuster weight ... compounding pharmacies that make weight-loss drugs, but they do not test the products. There is no FDA-approved generic version ...

(Bloomberg) -- Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and ... The FDA said in October that there was no longer a shortage of Lilly’s drugs and that making copies must ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Eli Lilly’s blockbuster obesity and diabetes drugs Zepbound and Mounjaro are no longer ... The shortage of the drug tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss ...

On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss ... agency's shortage list. Now that the FDA has decided tirzepatide is no longer ...

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients ...

The U.S. Food and Drug Administration removed Eli Lilly's (LLY.N), opens new tab blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely piling pressure on ...

All doses of Eli Lilly’s weight loss drugs Zepbound and Mounjaro are available in the United States after more than a year of being in shortage, according to the Food and Drug Administration’s ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in ...

Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in ... Administration determined that the drug shortage “is resolved,” reaffirming ...

The shortage of Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs is over ... “They are being cut off cold-turkey, their prescription no longer fillable,” he said in a statement.

News weighs on stocks of companies offering alternatives and some smaller ones developing their own drugs ... Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no ...